Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study investigated using baricitinib-loaded mesenchymal stem cell exosomes injected locally in an alopecia areata mouse model and found that this method improved hair regrowth better than baricitinib or exosomes alone, potentially offering a new therapeutic approach for treating alopecia areata.

This study identified two cytochrome P450 enzymes in Avicennia marina leaves that may contribute to the biosynthesis of triterpenoids, potentially responsible for the plant's medicinal properties.

This study observed distinct post-marketing safety signal patterns for baricitinib and tofacitinib in adult AA, influenced by their differing regulatory uses and real-world contexts, and emphasizes the need for future studies to validate these findings.

This study found that the methanolic heartwood extract of Avicennia marina significantly inhibited the enzyme 5 alpha-reductase type 1 in a cell-based assay, suggesting potential anti-androgenic effects for treating androgenic alopecia.

In this study, researchers found that niosomes, bilosomes, and spanlastic formulations can enhance the oral anticoagulation efficiency of rivaroxaban in rats, with spanlastic ranked as the most effective in prolonging clotting, prothrombin, and tail bleeding times compared to unprocessed rivaroxaban.

China approved Sinovac's flu vaccine, Japan approved RiUP for female hair loss, and Nippon Kayaku's three cancer drugs.

This study demonstrated that the IVL-DrugFluidic® platform is effective for mass-producing finasteride-loaded polymeric microspheres for long-acting injectables, maintaining stable drug release without an initial burst for a month.

This scoping review found that most of the 64 alopecia areata patients treated with upadacitinib in existing reports experienced significant hair regrowth, with mild side effects, but the authors call for larger studies to confirm these outcomes.

This study found that alkaloids isolated from Cucumis metuliferus fruit pulp demonstrated antiviral activity against IBDV in chicken embryo fibroblast cells and NDV in 10-day-old embryonated chicken eggs, while being non-cytotoxic.

This study found that oral administration of 7, 8–dihydroxyflavone in guinea pigs improved recovery from gentamicin-induced vestibular damage, suggesting potential therapeutic use for vestibular dysfunction in humans.

This study found that abrocitinib showed promising efficacy and safety in adolescents with moderate-to-severe alopecia areata, with significant hair regrowth observed over 10 months of treatment.

In this study, researchers developed and tested a gel containing apocynin-loaded nanoparticles that showed promising results in treating rheumatoid arthritis in rats, suggesting potential for novel topical treatments in inflammatory conditions.

This study found that a 50% ethanolic extract of Adiantum capillus had significant analgesic and anti-inflammatory effects in animals, particularly at the highest tested dose of 300 mg/kg.

This study reports that hedgehog pathway inhibitors, sonidegib and vismodegib, showed distinct adverse event patterns in real-world data, suggesting the need for further research to confirm these findings.

A new food supplement was highly effective in curing hair loss in young men.

This article reviews the potential of Acyzol, a zinc-containing drug, to treat and prevent zinc deficiency conditions, but it reports no new clinical findings.

The committee unanimously voted against recommending approval of the injectable cisplatin/epinephrine gel IntraDose for certain head and neck cancer patients, citing insufficient clinical benefit and concerns about toxicity in this study.

Upadacitinib is effective and safe for treating severe Alopecia Areata in adolescents.

This review discusses the capabilities of ethosomes as drug delivery carriers and reports improved outcomes in a clinical study with an ethosomal acyclovir formulation.

This study found that 2-hydroxy-1,4-naphthoquinone was the most effective inhibitor of steroid 5α-reductase, showing stronger inhibition than avicequinone C in HaCaT cell assays.

This review reports that sonidegib and vismodegib, two Hedgehog inhibitors used for treating advanced basal cell carcinoma, have similar efficacy and safety profiles, but differ in pharmacokinetics, with sonidegib achieving peak concentration more rapidly and reaching steady state later than vismodegib.

In this study, topical acyclovir significantly delayed hair growth initiation and completion in mice and reduced hair follicle size, suggesting potential inhibitory effects on hair growth.

This study reported that in a case series of three adolescents with alopecia areata and atopic dermatitis, treatment with 15 mg/day of upadacitinib led to rapid improvement in skin symptoms and significant hair regrowth over 12 months, with no severe adverse events observed.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.

This review explores the therapeutic potential of bee venom for treating various skin diseases, discussing its mechanisms and effects but reports no new clinical findings.

This report notes that while surgical excision is typically curative for squamous cell carcinoma, the authors suggest considering the intralesional use of cidofovir for its potential success without systemic toxicity.

This case study reported significant clinical improvement in a 26-year-old male with dissecting cellulitis of the scalp after treatment with upadacitinib, suggesting that JAK inhibitors may be a promising option for refractory cases, where standard treatments have limited success.

This study found that using a vibration anesthetic device during scalp mesotherapy significantly reduced pain in patients with androgenetic alopecia and alopecia areata compared to the non-vibration side.

In this case report, a 57-year-old man with severe atopic dermatitis, vitiligo, and alopecia areata showed rapid and significant improvement after treatment with the JAK1 inhibitor upadacitinib, suggesting its potential as an effective monotherapy for these co-existing conditions when conventional therapies fail.